Related Experiment Video
Updated: Jun 21, 2025
04:38
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
Published on: March 28, 2018
15.6K
Exploring potential plasma drug targets for cholelithiasis through multiancestry Mendelian randomization.
Xiaoduo Liu1, Lubo Shi2, Shutian Zhang2
1Department of Neurology and Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders.
International Journal of Surgery (London, England)
|July 8, 2024
Summary
This study identifies novel drug targets for gallstones (cholelithiasis) using Mendelian randomization. FUT3, NOE1, UGT1A6, and FKBP52 are potential targets in Europeans, while KLB and FGFR4 show promise in East Asians.
Area of Science:
- Genetics
- Pharmacology
- Gastroenterology
Background:
- Cholelithiasis (gallstones) presents a substantial global health and economic challenge.
- Novel pharmacological targets are crucial for improving gallstone treatment efficacy.
Purpose of the Study:
- To identify potential drug targets for cholelithiasis using a two-sample Mendelian randomization (MR) approach.
- To explore plasma proteomics data for genetic associations with gallstone disease in diverse populations.
Main Methods:
- Genome-wide association studies (GWAS) and plasma proteomics data were utilized.
- Two-sample Mendelian randomization (MR) analysis was performed in European and East Asian cohorts.
- Reverse MR, Steiger filtering, Bayesian colocalization, and phenome-wide MR were employed for validation and safety assessment.
Main Results:
- FUT3, NOE1, UGT1A6, and FKBP52 were identified as potential targets in Europeans.
- KLB and FGFR4 emerged as potential targets in East Asians.
- Protein-protein interaction analysis indicated involvement in bile acid metabolism; NOE1 and FGFR4 showed potential adverse effects.
Conclusions:
- Plasma proteins FUT3, NOE1, UGT1A6, and FKBP52 represent promising therapeutic targets for gallstone disease in European populations.
- KLB and FGFR4 show potential as targets for cholelithiasis treatment in East Asian individuals.
More Related Videos
Related Concept Videos
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
37
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
37
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
628
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
628
01:26Targets for Drug Action: Overview
6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K
01:14Hepatic Drug Clearance: Role of Transporters
54
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
54
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
514
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
514
01:29Drug Distribution: Plasma Protein Binding
5.5K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.5K